Danburstotug Biosimilar - Research Grade

Out of stock

Only %1 left

SKU

ICH5464-10mg

Add to Compare

Be the first to review this product

Danburstotug Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>90% by SDS-PAGE

Species Reactivity

Human

Target

PD-L1

Concentration

>1mg/ml

Isotype

IgG1 - lambda2

Host

CHO Cells

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q9NZQ7

Shipping Conditions

Blue ice

Background

ICH5464 is a research-grade biosimilar of danburstotug (IMC-001), an anti-PD-L1 monoclonal antibody originally developed by Sorrento Therapeutics and later advanced by ImmuneOncia. This product is an unconjugated, non-therapeutic analog built around the PD-L1 target and the human IgG1 (lambda) framework of the originator drug. It is intended strictly for research use only and is not a clinical drug or approved therapeutic. Danburstotug is notable among PD-L1-directed antibodies because its native IgG1 Fc retains antibody-dependent cellular cytotoxicity (ADCC) activity, giving it a dual mechanism that couples checkpoint blockade with direct immune-mediated killing of PD-L1-expressing target cells; many competing PD-L1 antibodies carry Fc modifications that silence ADCC. The biosimilar is manufactured to in-vivo research standards with low endotoxin and is available in bulk milligram-to-gram quantities, supporting reproducible use as a reference or benchmarking reagent. It is well suited to functional and in-vitro characterization studies, including binding, checkpoint-blockade, ADCC, and control experiments where a consistent, well-defined anti-PD-L1 IgG1 analog is required. Investigators should validate performance in their own assay systems. PD-L1 (programmed death-ligand 1; CD274, B7-H1; UniProt Q9NZQ7) is a type I transmembrane immune-checkpoint ligand of the B7 family. It engages the inhibitory receptor PD-1 on activated T cells, delivering a coinhibitory signal that dampens T-cell receptor signaling, proliferation, and cytokine production, thereby promoting peripheral tolerance. PD-L1 is expressed on antigen-presenting cells and many normal tissues and is frequently upregulated on tumor cells and in the tumor microenvironment, often driven by interferon-gamma, where it enables immune evasion. PD-L1 also binds CD80 (B7-1). Blocking the PD-1/PD-L1 axis restores antitumor T-cell activity and is a validated immuno-oncology strategy. Antibodies that additionally retain Fc effector function can drive ADCC against PD-L1-high cells.

Other Names

CD274

Purification Method

This monoclonal antibody was purified using Protein A

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Storage

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.